Home
Forms Library
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 2026

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 Preview on Page 1

See details

4.4 out of 5

22 votes

The document is a Prior Authorization Drug Attachment form for Hepatitis C agents issued by the Wisconsin Department of Health Services. It outlines the necessary information and documentation required from pharmacy providers and prescribers to submit a prior authorization request for hepatitis C treatment. The form includes sections for member information, prescription details, clinical information, and requires signatures from the prescriber.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Click ‘Get Form’ to open it in the editor.
Begin with SECTION I – MEMBER INFORMATION. Enter the member's name, ID number, and date of birth clearly.
Proceed to SECTION II – PRESCRIPTION INFORMATION. Fill in the date the prescription was written, prescriber's name, National Provider Identifier, address, and phone number.
Indicate the member’s proposed hepatitis C drug treatment regimen by listing the drug names, whether currently taking them, daily doses, and expected duration.
In SECTION III – CLINICAL INFORMATION, provide diagnosis codes and descriptions. Ensure to attach relevant medical records as specified.
Complete any additional questions regarding previous treatments and conditions that may affect drug usage.
Finally, sign in SECTION IV – AUTHORIZED SIGNATURE and include any additional information in SECTION V if necessary.

Start using our platform today for free to streamline your form completion process!

See more PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 versions

We've got more versions of the PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 form. Select the right PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 version from the list and start editing it straight away!

Versions	Form popularity	Fillable & printable
2020	4.4 Satisfied (22 Votes)
2018	4.8 Satisfied (42 Votes)
2017	4.5 Satisfied (36 Votes)
2017	4.3 Satisfied (46 Votes)

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

Can I use DocHub to create legal eSignatures on my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247?

Yes, you can utilize DocHub for signing any business and private documentation, including your PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247. All eSignatures you create with our tool are legally binding and court-admissible, as DocHub complies with criteria required by ESIGN and UETA. Save your completed paperwork with a detailed Audit Trail if needed.

Can I print my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 and finish it on my own?

When you choose analog ways of completing your PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247, you can easily download your file for printing. Search DocHub’s Forms & Templates catalog to get the exact file template you need and open it for editing or download it on your gadget in the format of your liking. It is possible to complete your form electronically and place your handwritten signature on it right after printing or eSign your file with DocHub.

What drugs are FDA approved for hep C?

BACKGROUND: Mavyret, Zepatier, and Vosevi are FDA-approved to treat chronic hepatitis C in patients without liver impairment or with mild liver impairment (Child-Pugh A).

Is MAVYRET approved by the FDA?

With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate. HCV is a highly infectious blood-borne disease affecting the liver. People recently infected, or those with acute HCV, may not have symptoms.

What is the oral drug for Hep C?

Ledipasvir/sofosbuvir (Harvoni) Ledipasvir inhibits HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of HCV NS5B RNA-dependent polymerase. The oral combination is indicated for treatment of adults with chronic hepatitis C infection with genotype 1, 4, 5, or 6.

Security and compliance

At DocHub, your data security is our priority. We follow HIPAA, SOC2, GDPR, and other standards, so you can work on your documents with confidence.

Learn more

Related forms

be ready to get more

Complete this form in 5 minutes or less

Get form

What is the FDA approved treatment for Hep C?

Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic (long-lasting) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). In June 2025, Mavyret was also approved by the FDA to treat acute (recently infected) HCV.

What are Pangenotypic drugs for Hep C?

There are now three pan-genotypic DAA regimens listed on the PBS: sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, and sofosbuvir plus velpatasvir plus voxilaprevir. The first-line regimens for treatment-naive people living with hepatitis C are sofosbuvir plus velpatasvir or glecaprevir plus pibrentasvir.

Which is better, Epclusa or MAVYRET?

When taken exactly as prescribed, both drugs are highly effective at curing this disease. Depending on your condition, you may only have to take Mavyret for 8 weeks compared with 12 weeks for Epclusa. However, your doctor may prescribe Epclusa if you have severe liver disease.

What is the new drug to cure hep C?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 15, 2025. The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir).

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 2026

Here's how it works

How to use or fill out PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247

See more PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 versions

Complete this form in 5 minutes or less

Got questions?

Can I use DocHub to create legal eSignatures on my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247?

Can I print my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 and finish it on my own?

What drugs are FDA approved for hep C?

Is MAVYRET approved by the FDA?

What is the oral drug for Hep C?

Security and compliance

Complete this form in 5 minutes or less

People also ask

What is the FDA approved treatment for Hep C?

What are Pangenotypic drugs for Hep C?

Which is better, Epclusa or MAVYRET?

What is the new drug to cure hep C?

Related links

Try more PDF tools